Dornier Medical Systems of Kennesaw, GA, has a new management team in place. COO James Haisler has added the title of president to his duties, replacing Karl Jonietz, who has left Dornier to pursue other opportunities.Other new members of the DMSI team
Dornier Medical Systems of Kennesaw, GA, has a new management team in place. COO James Haisler has added the title of president to his duties, replacing Karl Jonietz, who has left Dornier to pursue other opportunities.
Other new members of the DMSI team include Manfred Drax, vice president of finance and administration; John McCauley, director of marketing; Tom Gibson, director of national service; and Bryan Smith, director of lithotripsy.
In other news, the company's Dornier Surgical Products subsidiary is conducting pilot studies on its Image Analysis System (IAS), which is designed to improve the treatment and detection of prostate disease. IAS allows physicians to see the extent of tissue destruction beneath the surface using existing ultrasound systems and Dornier's analysis console. The technique holds promise for identifying cancer within the prostate and in guiding the administration of transrectal biopsy, according to the company.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.